The proteomic 2D-DIGE approach reveals the protein voltage-dependent anion channel 2 as a potential therapeutic target in epithelial thyroid tumours

Eugenia Mato, Sílvia Barceló-Batllori, Irene Orera, Laia Selva, Martina Corra, Cintia González, Olga Bell, Enrique Lerma, Antonio Moral, José Ignacio Pérez, Alberto de Leiva

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Abstract

© 2015 Elsevier Ireland Ltd. We investigated the role of VDAC2 in human epithelial thyroid tumours using proteomic 2D-DIGE analysis and qRT-PCR. We found a significant up-regulation of VDAC2 in thyroid tumours and in thyroid tumour cell lines (TPC-1 and CAL-62). We did not detect overexpression of VDAC2 in a normal thyroid cell line (Nthy-ori 3-1). Silico analysis revealed that two proteins, BAK1 and BAX, had a strong relationship with VDAC2. BAK1 gene expression showed down-regulation in thyroid tumours (follicular and papillary tumours) and in TPC-1 and CAL-62 cell lines. Transient knockdown of VDAC2 in TPC-1 and CAL-62 promoted upregulation of the BAK1 gene and protein expression, and increased susceptibility to sorafenib treatment. Overexpression of the BAK1 gene in CAL-62 showed lower sorafenib sensitivity than VDAC2 knockdown cells. We propose the VDAC2 gene as a novel therapeutic target in these tumours.
Original languageEnglish
Pages (from-to)37-45
JournalMolecular and Cellular Endocrinology
Volume404
DOIs
Publication statusPublished - 5 Mar 2015

Keywords

  • Epithelial thyroid tumours
  • Therapeutic target
  • Voltage-dependent anion channel 2

Fingerprint

Dive into the research topics of 'The proteomic 2D-DIGE approach reveals the protein voltage-dependent anion channel 2 as a potential therapeutic target in epithelial thyroid tumours'. Together they form a unique fingerprint.

Cite this